Compositions and methods for treating cns disorders
AssigneeSage Therapeutics, Inc.
InventorMaria Jesus Blanco-Pillado
Life of this patent
Estimating the term…
Abstract
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of using the compound of Formula (I) in the treatment of CNS-related disorders.
Claims196
A compound of Formula (I)
- or a pharmaceutically acceptable salt thereof, wherein
- Ring D is selected from
- Each of R1a, R1b, R2a, R2b, R3, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R13, R15, R16, R17, R20a, R20b, R20c, and R21, is -LA-R30;
- Each LA is independently selected from a bond and an optionally substituted branched or straight C1-6 alkylene chain, wherein up to two carbon atoms of LA are optionally and independently replaced by —NR′—, —S—, —O—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)C(O)—, —C(O)NR′—, —NR′C(O)—, —NR′C(O)O—, —S(O)2NR′—, —NR′S(O)2—, —C(O)NR′NR′—, —NR′C(O)NR′—, —OC(O)NR′—, —NR′NR′—, —NR′S(O)2NR′—, —S(O)—, or —S(O)2—;
- Each R30 is independently selected from R′, —OH, halo, —CN, —NO2, and —CF3;
- Each R′ is independently selected from —H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 alkyl-O—C1-6 alkyl, and an optionally substituted 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from N, O, and S, or
- R1a and R1b taken together form oxo, or
- R2a and R2b taken together form oxo, or
- R4a and R4b taken together form oxo, or
- R6a and R6b taken together form oxo, or
- R7a and R7b taken together form oxo, or
- R1a and R11b taken together form oxo, or
- R12a and R12b taken together form oxo, or
- R20a and R20b taken together form oxo;
- Each of R5 and R20c is independently selected from —H and optionally substituted C1-6 alkyl;
- R10 is —H, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkyl-O—C1-6 alkyl;
- Each of R31a and R31b is independently selected from —H, halo, C1-6 alkyl, and —OR32, wherein R32 is —H, C1-6 alkyl, or a 3-6-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from N, O, and S;
- m is 1 or 2;
- and
- n is 0, 1, or 2,
- provided that when one of R31a and R31b is —OR32, the other of R31a and R31b is —H.
The compound or pharmaceutically acceptable salt of any one of 2-16, 57-73, 99-120, or 147-152, wherein one of R2a and R2b is —H, and the other is —H, C1-6 alkyl optionally substituted with R′, —N(R′)2, or —O—R′.
A compound selected from
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.